Leukemia Cell Signaling Pathways: Recent Advances, Future Perspectives, and Potential Clinical Applications
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 16
Special Issue Editors
Interests: leukemia; DNA repair; DNA damage response; PARP inhibitor; Polθ inhibitor; bone marrow microenvironment; cell signaling; protein kinases; DNA methylation; transcription factor
Special Issue Information
Dear Colleagues,
Investigating cell signaling pathways has always been a hot topic in cancer research. Especially in relation to leukemia, this matter is becoming more and more explored because of the expression of common oncogenic kinase proteins, additional mutations via clonal evolution, and the bone marrow-mediated activation/alteration of intracellular signals in cells. While the former strongly involves leukemic malignant transformation, the latter two concern contributions to therapeutic resistance, driving disease relapse. Recent advances in this research area have improved the understanding of the cell signaling pathways in leukemogenesis and drug response. However, leukemia cells can evolve to acquire alternative signaling pathways to survive under therapeutic stress and reproduce more aggressive malignant cells, driving rapid relapses in patients. Therefore, further studies in the field of leukemia cell signaling are critical to enhance the knowledge in this area and to explore more efficient targeted therapies to eliminate disease relapse. As such, we are launching a Special Issue entitled “Leukemia Cell Signaling Pathways: Recent Advances, Future Perspectives, and Potential Clinical Applications” in Cancers; we are pleased to invite you to submit your research to this Special Issue.
The major aim of this Special Issue is to publish high-quality articles in basic, translational, and clinical research of leukemia cell signaling. Preferential articles must provide scientifically innovative aspects of cell signaling which are associated with leukemic transformation, drug resistance, and potential therapeutic discovery. Special consideration is directed to mechanistic studies, producing both in vitro and in vivo data, as well as employing modern cell/molecular biology technologies such as multi-omics analyses, genome editing, and single cell sequencing.
For this Special Issue, we welcome the submission of manuscripts in both the review and original research categories. The research theme of this Special Issue includes (but is not limited to) the following: (1) addressing current issues and discussing future perspectives in leukemia cell signaling; (2) reporting novel basic knowledge in this area; (3) mechanistic studies of cell signaling drug resistance in leukemia; (4) identification of potential therapeutic targets in cell signaling for the treatment of leukemia; and (5) leukemia clinical research using cell signaling-based interventions. We are particularly interested in studies relating to cell signaling in the bone marrow niche/microenvironment and the development of precision medicine in leukemia.
We look forward to receiving your contributions.
Dr. Bac Viet Le
Dr. Srinivas Chatla
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- leukemia
- cell signaling
- bone marrow microenvironment
- leukemic transformation
- drug resistance
- therapeutic discovery
- cell signaling inhibitors
- precision medicine
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
